Venmax Drugs & Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 225982,
    "name": "Venmax Drugs",
    "stock_name": "Venmax Drugs",
    "full_name": "Venmax Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/venmax-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.99",
    "chg": -0.51,
    "chgp": "-2.37%",
    "dir": -1,
    "prev_price": "21.50",
    "mcapval": "25.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531015,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE154G01022",
    "curr_date": "Jun 05, 03:30 PM",
    "curr_time": "20:49 PM",
    "last_traded_at": "Jun 05, 03:30 PM IST",
    "bse_nse_vol": "2.96 k",
    "exc_status": "Active",
    "traded_date": "Jun 05, 2026",
    "traded_date_str": "2026 06 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venmax-drugs-225982-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-ltd-is-rated-strong-sell-4017930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VenmaxDrugsPhar_mojoScore_4017930.png",
        "date": "2026-05-28 10:10:30",
        "description": "Venmax Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Feb 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 28 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd: Valuation Metrics Signal Heightened Risk Amidst Price Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venmax-drugs-pharmaceuticals-ltd-valuation-metrics-signal-heightened-risk-amidst-price-resilience-3995851",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VenmaxDrugsPhar_valuationdot_3995851.png",
        "date": "2026-05-18 08:00:26",
        "description": "Venmax Drugs & Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving to levels that challenge its price attractiveness. This article analyses these valuation changes in the context of historical trends, peer comparisons, and the company’s financial performance, highlighting the implications for investors amid a deteriorating quality grade and a micro-cap market capitalisation."
      },
      {
        "title": "Are Venmax Drugs & Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-venmax-drugs-pharmaceuticals-ltd-latest-results-good-or-bad-3993283",
        "imagepath": "",
        "date": "2026-05-15 19:19:39",
        "description": "The latest financial results for Venmax Drugs & Pharmaceuticals Ltd reveal a company undergoing significant operational changes. In the quarter ended March 2026, the company reported net sales of ₹3.94 crores, reflecting a substantial year-on-year growth of over 1,093.94%, indicating a strong top-line expansion from the previous year. This growth, however, has not translated into meaningful profitability, as the net profit for the same quarter was only ₹0.11 crores, which represents a decline of 85.90% compared to the prior year.\n\nThe operating margin for the quarter was recorded at just 0.25%, a modest recovery from the negative margins seen in the previous year, but still indicative of limited operational efficiency. The profit after tax (PAT) margin also showed a decrease, standing at 2.79%, significantly lower than the exceptionally high margin of 236.36% from the same quarter last year, which was heavi..."
      },
      {
        "title": "Venmax Drugs Q4 FY26: Explosive Revenue Growth Masks Razor-Thin Margins and Eroding Promoter Confidence",
        "link": "https://www.marketsmojo.com/news/result-analysis/venmax-drugs-q4-fy26-explosive-revenue-growth-masks-razor-thin-margins-and-eroding-promoter-confidence-3992851",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VenmaxDrugsPhar_quaterlyResult_3992851.png",
        "date": "2026-05-15 10:01:49",
        "description": "Venmax Drugs & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹30.00 crores, reported a dramatic turnaround in its Q4 FY26 results, posting a net profit of ₹0.11 crores compared to ₹0.78 crores in Q4 FY25. Whilst the company achieved remarkable revenue growth of 1,093.94% year-on-year, the headline numbers conceal troubling operational realities: operating margins remain anaemic at just 0.25%, promoter shareholding has declined sharply to 13.80%, and the stock trades at a concerning 34.35 times trailing earnings despite fundamental weaknesses. The shares gained 1.74% on May 15, 2026, trading at ₹25.70, but remain 30.47% below their 52-week high of ₹36.96."
      },
      {
        "title": "Are Venmax Drugs & Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-venmax-drugs-pharmaceuticals-ltd-latest-results-good-or-bad-3991700",
        "imagepath": "",
        "date": "2026-05-14 19:17:39",
        "description": "The latest financial results for Venmax Drugs & Pharmaceuticals Ltd indicate a complex operational landscape. In the quarter ending December 2025, the company reported net sales of ₹1.55 crores, reflecting a quarter-on-quarter growth of 17.42% from ₹1.32 crores in September 2025. This growth is notable, but it is important to recognize that the year-on-year increase of 675.00% is primarily due to a very low base from the previous year, where sales were minimal.\n\nThe net profit for the same quarter was ₹0.03 crores, which is a 50.00% increase from the ₹0.02 crores reported in the prior quarter. However, the profit margins remain thin, with a PAT margin of 1.94%, a modest improvement from a significantly negative margin of -250.00% in the same quarter last year. This indicates that while the company is returning to profitability after several quarters of losses, the margins are still not robust enough to prov..."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-ltd-is-rated-strong-sell-3991083",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VenmaxDrugsPhar_mojoScore_3991083.png",
        "date": "2026-05-14 10:10:32",
        "description": "Venmax Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Feb 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 14 May 2026, providing investors with the latest perspective on the company’s position."
      },
      {
        "title": "When is the next results date for Venmax Drugs & Pharmaceuticals Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-venmax-drugs-pharmaceuticals-ltd-3980408",
        "imagepath": "",
        "date": "2026-05-07 23:16:30",
        "description": "The next results date for Venmax Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026...."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-ltd-is-rated-strong-sell-3970017",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VenmaxDrugsPhar_mojoScore_3970017.png",
        "date": "2026-04-30 10:10:20",
        "description": "Venmax Drugs & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      }
    ],
    "total": 86,
    "sid": "225982",
    "stock_news_url": "https://www.marketsmojo.com/news/venmax-drugs-pharmaceuticals-225982"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-May-2026",
      "details": "Newspaper Advertisement of the Audited Financial results for the Quarter and Year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Statement Of Deviation & Variation",
      "datetime": "15-May-2026",
      "details": "Statement of Deviation & variation for the Quarter and Year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Audited Financial Results For The Quarter And Year Ended March 31 2026",
      "datetime": "14-May-2026",
      "details": "Audited Financial Results for the Quarter and Year ended March 31 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2026-05-28 10:10:30

Venmax Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Feb 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 28 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Venmax Drugs & Pharmaceuticals Ltd: Valuation Metrics Signal Heightened Risk Amidst Price Resilience

2026-05-18 08:00:26

Venmax Drugs & Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving to levels that challenge its price attractiveness. This article analyses these valuation changes in the context of historical trends, peer comparisons, and the company’s financial performance, highlighting the implications for investors amid a deteriorating quality grade and a micro-cap market capitalisation.

Read full news article

Are Venmax Drugs & Pharmaceuticals Ltd latest results good or bad?

2026-05-15 19:19:39

The latest financial results for Venmax Drugs & Pharmaceuticals Ltd reveal a company undergoing significant operational changes. In the quarter ended March 2026, the company reported net sales of ₹3.94 crores, reflecting a substantial year-on-year growth of over 1,093.94%, indicating a strong top-line expansion from the previous year. This growth, however, has not translated into meaningful profitability, as the net profit for the same quarter was only ₹0.11 crores, which represents a decline of 85.90% compared to the prior year. The operating margin for the quarter was recorded at just 0.25%, a modest recovery from the negative margins seen in the previous year, but still indicative of limited operational efficiency. The profit after tax (PAT) margin also showed a decrease, standing at 2.79%, significantly lower than the exceptionally high margin of 236.36% from the same quarter last year, which was heavi...

Read full news article

Venmax Drugs Q4 FY26: Explosive Revenue Growth Masks Razor-Thin Margins and Eroding Promoter Confidence

2026-05-15 10:01:49

Venmax Drugs & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹30.00 crores, reported a dramatic turnaround in its Q4 FY26 results, posting a net profit of ₹0.11 crores compared to ₹0.78 crores in Q4 FY25. Whilst the company achieved remarkable revenue growth of 1,093.94% year-on-year, the headline numbers conceal troubling operational realities: operating margins remain anaemic at just 0.25%, promoter shareholding has declined sharply to 13.80%, and the stock trades at a concerning 34.35 times trailing earnings despite fundamental weaknesses. The shares gained 1.74% on May 15, 2026, trading at ₹25.70, but remain 30.47% below their 52-week high of ₹36.96.

Read full news article

Are Venmax Drugs & Pharmaceuticals Ltd latest results good or bad?

2026-05-14 19:17:39

The latest financial results for Venmax Drugs & Pharmaceuticals Ltd indicate a complex operational landscape. In the quarter ending December 2025, the company reported net sales of ₹1.55 crores, reflecting a quarter-on-quarter growth of 17.42% from ₹1.32 crores in September 2025. This growth is notable, but it is important to recognize that the year-on-year increase of 675.00% is primarily due to a very low base from the previous year, where sales were minimal. The net profit for the same quarter was ₹0.03 crores, which is a 50.00% increase from the ₹0.02 crores reported in the prior quarter. However, the profit margins remain thin, with a PAT margin of 1.94%, a modest improvement from a significantly negative margin of -250.00% in the same quarter last year. This indicates that while the company is returning to profitability after several quarters of losses, the margins are still not robust enough to prov...

Read full news article

Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2026-05-14 10:10:32

Venmax Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Feb 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 14 May 2026, providing investors with the latest perspective on the company’s position.

Read full news article

When is the next results date for Venmax Drugs & Pharmaceuticals Ltd?

2026-05-07 23:16:30

The next results date for Venmax Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026....

Read full news article

Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2026-04-30 10:10:20

Venmax Drugs & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

View All News